We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+44.61%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$502M
AUM Growth
-$46.6M
Cap. Flow
-$131M
Cap. Flow %
-26.01%
Top 10 Hldgs %
39.38%
Holding
180
New
41
Increased
13
Reduced
50
Closed
76

Top Buys

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.2M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$10.6M
3
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$7.73M
4
SAGE
Sage Therapeutics
SAGE
+$6.1M
5
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$5.3M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$12.7M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$11.3M
3
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$11.1M
4
UTHR icon
United Therapeutics
UTHR
+$9.43M
5
CLDX icon
Celldex Therapeutics
CLDX
+$6.76M

Sector Composition

Rank Sector Weight
1 Healthcare 39.26%
2 Consumer Staples 0%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$2.93M 0.58%
+23,131
New +$2.62M
BIIB icon
52
Biogen
BIIB
$30B
$2.93M 0.58%
10,962
+9,840
+877% +$2.09M
RVNC
53
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.7M 0.54%
+100,000
New +$2.03M
COGT icon
54
Cogent Biosciences
COGT
$6.65B
$2.43M 0.48%
162,766
-87,234
-35% -$1.2M
STSA
55
CALL
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$2.4M 0.48%
+400,000
New +$2.27M
DCPH
56
CALL
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.27M 0.45%
+122,600
New +$1.92M
INSM icon
57
CALL
Insmed
INSM
$21.4B
$2.15M 0.43%
+100,000
New +$2.4M
SRPT icon
58
Sarepta Therapeutics
SRPT
$1.57B
$1.86M 0.37%
16,809
-8,191
-33% -$826K
LYRA
59
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.72M 0.34%
6,874
-73
-1% -$21.6K
MIST icon
60
CALL
Milestone Pharmaceuticals
MIST
$138M
$1.66M 0.33%
180,300
-32,100
-15% -$243K
CINC
61
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$1.48M 0.3%
+45,100
New +$1.27M
AKRO
62
CALL
DELISTED
Akero Therapeutics
AKRO
$1.39M 0.28%
+40,900
New +$626K
ESPR
63
CALL
DELISTED
Esperion Therapeutics
ESPR
$1.34M 0.27%
+200,000
New +$1.37M
VKTX icon
64
Viking Therapeutics
VKTX
$3.7B
$1.26M 0.25%
463,156
-372,119
-45% -$1.22M
ICPT
65
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.19M 0.24%
85,200
-19,800
-19% -$319K
GERN icon
66
CALL
Geron
GERN
$828M
$1.17M 0.23%
+500,000
New +$1.12M
ETNB
67
DELISTED
89bio
ETNB
$1.16M 0.23%
+200,000
New +$879K
OCUL icon
68
Ocular Therapeutix
OCUL
$1.79B
$1.1M 0.22%
+265,000
New +$1.33M
XFOR icon
69
X4 Pharmaceuticals
XFOR
$375M
$973K 0.19%
18,954
-37,038
-66% -$1.28M
CLNN icon
70
CALL
Clene
CLNN
$64M
$903K 0.18%
+16,130
New +$1.07M
BLU
71
CALL
DELISTED
BELLUS Health Inc.
BLU
$900K 0.18%
85,200
-14,800
-15% -$157K
MCRB icon
72
Seres Therapeutics
MCRB
$46.8M
$843K 0.17%
6,566
-20,465
-76% -$2.1M
BCLI
73
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$839K 0.17%
12,662
-4,233
-25% -$212K
STSA
74
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$815K 0.16%
136,059
-517,389
-79% -$2.93M
DSGN icon
75
PUT
Design Therapeutics
DSGN
$761M
$811K 0.16%
+48,500
New +$965K
1 2
3
4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Ikarian Capital held 180 positions worth $502M, down 8.5% from $548M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Ikarian Capital withdrew a net $131M in Q3 2022, closing 76 positions and reducing 50 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $12.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 39% of assets, down from 43% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Prometheus Biosciences, Inc. Common Stock worth $13.6M.

  • Ikarian Capital's largest Q3 2022 buy was Prometheus Biosciences, Inc. Common Stock: 231,181 shares worth $13.6M.
  • Ikarian Capital added most to IVERIC bio, Inc. Common Stock in Q3 2022, an estimated $12.2M increase.
  • Ikarian Capital's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $11.1M.
  • Ikarian Capital fully exited Karuna Therapeutics, Inc. Common Stock in Q3 2022, selling an estimated $12.7M.
  • Ikarian Capital's ten largest holdings make up 39% of its $502M portfolio in Q3 2022.
  • Ikarian Capital opened 41 new positions and closed 76 in Q3 2022.
  • Ikarian Capital's portfolio value fell 8.5% quarter-over-quarter to $502M.

Based on Ikarian Capital's 13F filing for Q3 2022, filed 14 Nov 2022.